Leucadia Therapeutics LLC, a biotechnology company focused on treating and preventing Alzheimer’s disease, and Methuselah Foundation, a public charity incentivizing innovation in regenerative medicine, today announced a joint partnership to develop a novel therapeutic strategy to treat Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia in the elderly, affecting over 5 million people in the USA. Affected individuals have difficulty creating new memories, and problems with language, mood and reasoning.  As the disease progresses, patients become withdrawn and bodily functions decline, leading to death within 3-9 years of diagnosis. No current drugs or treatments slow or halt the relentless progression of Alzheimer’s disease.

2014 was a year to remember. With a $10,000 Methuselah Prize awarded to Dr. Huber Warner of the National Institute on Aging’s Interventions Testing Program, the first six teams officially announced for the New Organ Liver Prize, and our first Organovo 3D printer awarded to the Yale School of Medicine, we’ve certainly been keeping busy.

$10,000 Methuselah Prize awarded to Dr. Huber Warner of the National Institute on Aging.

News and updates from Methuselah since launching the New Organ Liver Prize in December, 2013.